Kira Pharmaceuticals Announces $ 53.5 Million Series B + Funding to Advance LOGIC Drug Discovery Platform and Targeted Complement Therapies Pipeline
CAMBRIDGE, Mass. and SUZHOU, China, January 7, 2021 / PRNewswire / – Kira Pharmaceuticals, a global biotechnology company pioneering a new generation of complement-targeted therapies to treat immune-mediated diseases, today announced the first close of an oversubscribed program $ 53.5 million Series B + financing. The financing was co-led by RA Capital Management and Vivo Capital, with the participation of Foresite Capital and APlus Partners. Existing investors, including Quan Capital and Qiming Venture Partners United States, also participated in the first closing.
“While the complement system has historically been difficult to target given its complexity, we believe our LOGIC drug discovery platform allows us to approach complement mediation in new and different ways, unlocking transformative therapies for them. patients, ”said Frederick Beddingfield, MD, PhD, CEO of Kira Pharmaceuticals. “We are honored to have the support of leading global investors as we continue to advance our core asset P014, a bi-functional biologic soon to enter clinical practice and a pipeline of important complement-targeted therapies for patients. in need. ”
With a therapeutic focus on inflammatory and autoimmune diseases and oncology, Kira intends to advance three complement-targeted therapies at the clinic over the next 18 months. Kira’s most advanced program, P014, is a first-class biological molecule with a unique mechanism of action designed to inhibit upstream and downstream complement targets. By regulating two distinct limiting steps in the complement activation cascade critical for disease development, P014 provides a potent and selective approach to complement inhibition. P014 was also designed with extended half-life and potency, with the ability to self-administer at home.
“We are delighted with the rapid progress that Kira Pharmaceuticals has made with its lead program, P014, a drug with a truly new mechanism of action, which will soon be implemented in the clinic,” said Matthieu hammond, PhD, director at RA Capital Management. “With an intelligent drug discovery platform, a broad portfolio of therapies and a leading team, we believe Kira is at the forefront of defining a new way to target complement and deliver immune modulation. long-acting. “
“We are delighted to embark on this partnership with the Kira Pharma team and look forward to the advancement of the breakthrough therapeutic supplement P014 in the clinic,” said Dandan dong, PhD., Managing Director of Vivo Capital. “With a world-class management team and global infrastructure, we believe Kira is in a unique position to leverage its expertise and scientific resources to rapidly bring innovative therapies to patients with disease-mediated disease. the complement. “
About Kira Pharmaceuticals
Kira Pharmaceuticals is a biotechnology company that develops complement-targeted therapies to treat immune-mediated diseases. Through its LOGIC drug discovery platform, the company is committed to advancing world-class, best-in-class therapies to transform the lives of patients with complement-related illnesses. With offices in Cambridge, Massachusetts and an R&D center in Suzhou, China, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies for patients around the world.
For more information, please visit www.kirapharma.com.
SOURCE Kira Pharmaceuticals